Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy

Introduction Cancer treatment underwent significant changes in the last few years with the introduction of novel treatments targeting the immune system. Objectives The objective of this review is to discuss novel anticancer drugs including kinase inhibitors, biologics and cellular therapy with CAR-T...

Full description

Saved in:
Bibliographic Details
Published inInflammation research Vol. 74; no. 1; p. 41
Main Authors Abdo, Elia-Luna, Ajib, Imad, El Mounzer, Jason, Husseini, Mohammad, Kalaoun, Gharam, Matta, Tatiana-Maria, Mosleh, Reine, Nasr, Fidel, Richani, Nour, Khalil, Alia, Shayya, Anwar, Ghanem, Hady, Faour, Wissam H.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.12.2025
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Introduction Cancer treatment underwent significant changes in the last few years with the introduction of novel treatments targeting the immune system. Objectives The objective of this review is to discuss novel anticancer drugs including kinase inhibitors, biologics and cellular therapy with CAR-T cells. Methods Most recent research articles were extracted from PubMed using keywords such as “kinases inhibitors”, “CAR-T cell therapy”. Results and discussion The number of kinase inhibitors is significantly increasing due to their demonstrated effectiveness in combination with biologics. CAR-T represented a major breakthrough in the field. Also, it focused on their mechanisms of action and the rational of their use either alone or in combination in relation to their modes of action.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1023-3830
1420-908X
1420-908X
DOI:10.1007/s00011-025-02008-5